Researchers from the University of Wyoming in Laramie found that inhibiting several genes could reverse the damages caused by loss of "pRb" gene which gets inactivated in human cancers.
David S Fay, a researcher from the Molecular Biology Department at the University and his colleagues used a strain of nematode worms that carried a mutation in a gene similar to "LIN-35".
This gene, "LIN-35" in worms and "pRb" in humans, is thought to control at least several aspects of tumour progression including cancer cell growth and survival.
The researchers systematically inactivated other individual genes in the genome of the mutant LIN-35 worms.
As they deactivated various genes, scientists identified those that led to a reversal of defects caused by the loss of LIN-35, suggesting that they could be used as targets for anti-cancer therapies.
"We hope that by carrying out basic genetic research on one of the most widely implicated human cancer genes, that we can contribute to the arsenal of diverse therapeutic approaches used to treat and cure many types of cancer," Fay said.
The study was published in the journal Genetics.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
